For Healthcare Professionals

When blood tells you what imaging cannot yet confirm.

At critical inflection points in treatment and follow-up, ctDNA-MRD often detects minimal residual disease weeks before imaging: data, not guesswork.

EHA 2024 · HR 4.61 (p<0.0001) for 18-month OS

See Clinical Evidence

"I founded LIQOMICS to close a gap I kept meeting in the clinic: too many cancer patients have no reliable way of knowing whether their disease will return, and no molecular basis for treating them as individuals."

Sven Borchmann, MD, PhD Founder & Managing Director, LIQOMICS

Where ctDNA Adds Clarity

Three decision points. One blood draw.

Diagnosis

Tumor genotyping without biopsy

Profile the full genetic tumor landscape from a single blood draw. No biopsy bias, no sampling gap. Additionally, MRD tracking for your patient is made possible.

Mid-Treatment

Escalate or de-escalate at cycle 2

Get fast, accurate insight into how each patient is responding to treatment, enabling personalized clinical decisions.

Post-Treatment

Surveillance after treatment completion

Serial ctDNA monitoring has detected molecular relapse significantly earlier than imaging in multiple published studies across cancers.

The detection window

ctDNA rises and is often detectable months before imaging shows any change.

Schematic representation of liquid biopsy testing compared to imaging over the time course of treatment and surveillance.

Clinical Evidence

Peer-reviewed validation across three independent cohorts.

LymphoVista is clinically validated in prospective studies published in Blood, HemaSphere, and Med. Our evidence covers Hodgkin lymphoma, LBCL, and CNS lymphoma.

Advanced Hodgkin lymphoma: MRD-2 after BrECADD predicts 4-year outcome with exceptional accuracy

97.4% vs. 52.0% 4-year PFS (MRD-neg. vs. MRD-pos.)

MRD-negative MRD-positive

72 patients from the GHSG HD21 trial (BrECADD vs. eBEACOPP). LymphoVista HL assessed ctDNA-MRD after 2 cycles of chemotherapy. MRD negativity after cycle 2 predicted 4-year progression-free survival with a hazard ratio that exceeds any single biomarker previously validated in lymphoma. Crucially, the prognostic signal was independent of PET-2 result: MRD-negative, PET-positive patients fared as well as MRD-negative, PET-negative patients, adding a molecular layer to equivocal imaging findings.

HR 25.4 95% CI 12.5–51.7 · p<0.0001

18.5% MRD-positive rate

Heger et al., Blood 2026 · Mattlener et al., Blood 2024

Relapsed/refractory LBCL: quantitative MRD monitoring stratifies survival and risk category after salvage

77% vs. 33% 18-month OS (MRD-neg. vs. MRD-pos.)

MRD-negative MRD-positive

Number at risk

33 33 32 32 28 25 22

63 48 41 26 20 19 16

88 patients with relapsed or refractory large B-cell lymphoma (LBCL); 326 samples across 131 treatment lines. LymphoVista distinguished patients responding to salvage therapy from those who were not. Quantitative ctDNA reduction (depth of response) provided further risk differentiation beyond binary MRD status. MRD-positive patients were ten times more likely to relapse than MRD-negative patients.

HR 4.61 p<0.0001 · 18-month PFS 81% vs. 5%

10× More likely to remain in remission (MRD-neg. vs. MRD-pos.)

Schleifenbaum et al., EHA 2024 · Mattlener et al., EHA 2024

CNS lymphoma: plasma-based ctDNA detects peripheral residual disease and predicts relapse without CSF sampling

84.9% vs. 0% 2-year FFS (PRD-neg. vs. PRD-pos.)

PRD-negative PRD-positive

Number at risk

17 17 15 12 11 9 6 5 4

4 4 2 1 0 0 0 0 0

57 patients with primary or secondary CNS lymphoma. LymphoVista detected peripheral residual disease (PRD) from plasma, without CSF. Patients with PRD after induction had a 2-year failure-free survival of 0%, versus 84.9% in PRD-negative patients. Plasma-based genotyping was feasible in 83.4% of patients.

HR 6.60 MOP-C index vs. IELSG (per risk group)

83.4% Feasibility of plasma-based genotyping

Heger et al., Blood 2024

All LIQOMICS clinical evidence cited is from independent, peer-reviewed publications. LymphoVista is a laboratory-developed test (LDT).

Clinical Decision Support

Mapping ctDNA-MRD to the treatment continuum.

LymphoVista supports clinical decision-making across the full treatment trajectory. The timeline below maps each clinical landmark to the relevant evidence and decision support.

Diagnosis / Baseline profiling

LymphoVista / CancerVista

Essential baseline for all solid tumors and lymphomas. Tissue accepted for baseline genotyping when plasma yield is insufficient.

Future MRD+ Identifies the exact mutations a later test must re-detect to call relapse

Future MRD− Sets the sensitivity threshold a later result must clear to be trusted as clean

Plasma genotyping establishes a patient-specific molecular fingerprint for downstream MRD monitoring. Enables tumor characterization, risk stratification, and identification of actionable targets, even when tissue is insufficient.

Post-surgery / Risk stratification

CancerVista

MRD+ Adjuvant therapy

MRD− Consider observation; spare unnecessary treatment

MRD positivity after curative-intent surgery identifies patients at elevated relapse risk who benefit from adjuvant therapy. MRD negativity safely supports observation and may spare unnecessary chemotherapy. CRC DYNAMIC (NEJM 2022): HR 11.99. Bladder IMvigor011 (NEJM 2025): HR 6.34.

Early response / During induction

LymphoVista HL

MRD adds to equivocal PET.

MRD+ Consider MDT discussion about treatment intensification

MRD− Continue standard therapy with confidence

LymphoVista assesses MRD after just 2 cycles of induction chemotherapy in Hodgkin lymphoma (BrECADD/eBEACOPP). 4-year PFS 97.4% vs. 52.0%. Signal is independent of PET-2 status, adding information to equivocal imaging. [1, 2]

End of treatment / Consolidation decision

LymphoVista / CancerVista

MRD+ Escalation or serial monitoring

MRD− Supports de-escalation, observation

MRD positivity at EOT is a strong predictor of relapse across solid tumor types. NSCLC meta-analysis (30 studies): HR 11.19 PFS. Head & neck (MAESTRO): HR 27.4. LBCL relapsed/refractory: HR 4.61 OS. [3]

Treatment monitoring / During systemic therapy

CancerVista

Informs early treatment switching decisions before imaging confirmation. Applicable to all solid tumor types.

Rising / persistent Signals resistance

Decreasing Indicates response

Serial ctDNA provides a real-time efficacy signal across all systemic modalities. Decreasing ctDNA indicates response; persistent or rising ctDNA signals resistance.

Surveillance / Follow-up & relapse

LymphoVista / CancerVista

MRD+ Earlier intervention while disease burden is lowest. Lead-time advantage vs. imaging-triggered relapse management.

MRD− Continue routine surveillance

Serial ctDNA has detected molecular relapse significantly earlier than imaging in published external studies, with median lead times of 5 to 7 months reported across tumor types. CancerVista additionally tracks clonal evolution and emerging resistance mutations over time. LymphoVista is clinically validated in the lymphoma surveillance setting.

Ready to explore a case?

Our clinical team is available for case review.

Scientific & Clinical Partners

Test Specifications

Choose the right test for your patient.

Clinically Validated

(D)LBCL Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Burkitt Lymphoma CNS Lymphomas

Target Genes 76

Genomic Regions 715

mAF ≥0.5% · Sensitivity 93.86% · Specificity >99%

6.69 × 10⁻⁶

Sensitivity 100% · Specificity 100% · Accuracy 100%

Guideline NCCN v1.2025

Clinically Validated

Hodgkin Lymphoma

Target Genes 33

Genomic Regions 305

mAF ≥0.5% · Sensitivity 91.27% · Specificity 99.99%

6.54 × 10⁻⁶

Sensitivity 100% · Specificity 100% · Accuracy 100%

Guideline NCCN v1.2025

Sample volume

20 ml blood

Sample type

Tissue accepted
for baseline genotyping

Turnaround

10-15 working days

Ordering Process

Four steps. Collection kit provided by us.

Order the test

Request via our contact form or by phone. We send a collection kit and all required materials directly to your practice.

Take the sample

A routine 20 ml blood draw into the tubes provided in our collection kit. No special equipment or preparation required.

Lab analysis

ctDNA and MRD analysis performed in Cologne, Germany. Turnaround 10-15 working days.

Receive the report

A structured clinical report delivered directly to you. Results include detailed genotyping results, MRD trajectory, and clinical interpretation.

Ready to submit your first case?

We'll get a test kit to your clinic right away.

Want the full clinical picture first? See the LymphoVista Service Profile in our Clinical Resources below.

For Your Patients

The piece that connects you and your patient.

A short, plain-language guide explaining ctDNA-MRD testing, sample collection, and what the results mean: ready to hand to your patients.

For Your Practice

From first case to routine use.

GoÄ Reimbursement Support

Pre-configured billing codes and documentation templates for German clinics.

Encrypted Report Delivery

Results delivered as an encrypted PDF. All data processed and stored in Germany under GDPR.

Clinical Interpretation Support

Direct access to our clinical team for report interpretation and case discussion, by phone or email.

Data Residency: Germany & the EU

All samples processed in Cologne. No data transfer outside Germany or the EU.

Clinical Resources

Forms & Materials

Form

Test Request Form

Ready-to-print form for patient data and sample submission.

Information

Submission Information

Sample packaging, shipping, and handling instructions.

Profile

LymphoVista Service Profile

Comprehensive documentation for LymphoVista and LymphoVista HL. Includes per-indication clinical and analytical data.

From question to clinical decision

Precise MRD Detection. Confident Clinical Decisions.

Use your patients' ctDNA as a clinical compass.